NCT04550702View on ClinicalTrials.gov

Predictors for Retreatement of OAB After DC Mirabegron

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Recurrence of Overactive Bladder Syndrome
Interventions
DRUG

Mirabegron 25mg

Mirabegron 25 mg per day

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT04550702 - Predictors for Retreatement of OAB After DC Mirabegron | Biotech Hunter | Biotech Hunter